Company news
Vectus Biosystems Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
FDA Pre-IND feedback for VB0004
November 15, 2026
Appointment of Prof Tamera Corte as Chief Clinical Advisor
November 8, 2026
Notification regarding unquoted securities - VBS
October 30, 2026
Quarterly Activities & Appendix 4C Cash Flow Reports
October 29, 2026
Quarterly Activities & Appendix 4C Cash Flow Reports
October 29, 2026
Results of 2026 AGM
October 27, 2026
2026 AGM Presentations
October 27, 2026
FDA Pre-IND Meeting Request Granted for VB0004
September 29, 2026
2026 Notice of Annual General Meeting & Proxy Form
September 25, 2026
2026 Corporate Governance Statement & Appendix 4G
September 18, 2026
Annual Report to shareholders
September 18, 2026
Date of 2026 Annual General Meeting
September 9, 2026
Change of Director's Interest Notice - MS
September 4, 2026
Cleansing Notice
September 2, 2026
Application for quotation of securities - VBS
September 2, 2026
Full Year Statutory Accounts
August 30, 2026
Preliminary Final Report
August 30, 2026
Cleansing Notice
July 29, 2026
Application for quotation of securities - VBS
July 29, 2026
Quarterly Activities & Appendix 4C Cash Flow Reports
July 28, 2026
Placement of Shares
May 22, 2026
Appointment of Dr Tara Speranza as CEO & CTO
May 7, 2026
VB4-P5 Renal Compound Transaction Settled
April 13, 2026
Half Year Report & Appendix 4D
February 26, 2026
Quarterly Activities & Appendix 4C Cash Flow Reports
January 30, 2026
Response to ASX Query Letter
November 11, 2025
Reinstatement to Quotation
October 17, 2025
VB4-P5 Renal Compound Transaction
October 17, 2025
Suspension from Quotation
October 17, 2025
Trading Halt
October 15, 2025
Pause in Trading
October 15, 2025
Preliminary Final Report
August 29, 2025
Agreement with C14 Consulting Group
August 30, 2024
Passing of Vectus CEO
May 20, 2024
Quarterly Activities/Appendix 4C Cash Flow Report
October 31, 2023
Preliminary Final Report - Appendix 4E
August 30, 2023
Half Yearly Report & Appendix 4D
February 24, 2023
Issue Of Shares Under Placement
December 1, 2022
Vectus - $3.5 million placement
November 22, 2022
Completion of Phase Ia for VB0004
September 14, 2022
Completion of Second M.A.D. Study for VB0004
August 8, 2022
Quarterly Activities Report & Appendix 4C
July 28, 2022
Completion of Final S.A.D. Study and First M.A.D. Study
May 25, 2022
Half Yearly Report and Appendix 4D
February 25, 2022
A Significant Milestone for VB0004
February 20, 2022
Chairman & CEO Address to Shareholders
January 24, 2022
Third S.A.D. Group Reviewed By Trial Safety Review Committee
November 28, 2021
Response to ASX Price and Volume Query
October 19, 2021
Update on Phase I Human Trial
September 6, 2021
Successful Completion of First Group in Phase I Human Trial
August 23, 2021
Decks
The 5 newest of 11 decks. Every deck is listed under its year.
- Shareholder Meeting (October 2026)
Shareholder meeting · 10 slides · Oct 28, 2026
- Investor Presentation (May 2026)
Investor deck · 21 slides · May 13, 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 11 slides · Nov 26, 2025
- Shareholder Meeting (November 2024)
Shareholder meeting · 27 slides · Nov 27, 2024
- Shareholder Meeting (November 2023)
Shareholder meeting · 29 slides · Nov 22, 2023